論文・総説 - 田中　真二

1. Shimada S, Tanaka S. The chronicles of hepatocellular carcinoma classification: Subtyping, modeling, and treatment. Hepatology. 2024.02; 79 (2): 261-263. ( PubMed, DOI )

2. Tsukihara S, Akiyama Y, Shimada S, Hatano M, Igarashi Y, Taniai T, Tanji Y, Kodera K, Yasukawa K, Umeura K, Kamachi A, Nara A, Okuno K, Tokunaga M, Katoh H, Ishikawa S, Ikegami T, Kinugasa Y, Eto K, Tanaka S. Delactylase effects of SIRT1 on a positive feedback loop involving the H19-glycolysis-histone lactylation in gastric cancer. Oncogene. 2024; 44 (11): 724- in press. ( PubMed, DOI )

3. Igarashi Y, Akiyama Y, Shimada S, Watanabe S, Hatano M, Kodera K, Okazaki K, Tanji Y, Tsukihara S, Taniai T, Nara A, Yamane M, Kamachi A, Umemura K, Yasukawa K, Ono H, Akahoshi K, Tanabe M, Haruki K, Furukawa K, Ikegami T, Tanaka S. Identification and clinical implications of endogenous retrovirus elements suppressed by SETDB1 in hepatocellular carcinoma. JHEP Reports. 2024; in press. ( DOI )

4. Taniai T, Shimada S, Akiyama Y, Hatano M, Yasukawa K, Igarashi Y, Tsukihara S, Tanji Y, Kodera K, Okazaki K, Haruki K, Nara A, Yagi K, Akahoshi K, Ban D, Asahina Y, Ikegami T, Tanabe M, Tanaka S. Integrative transcriptome profiling elucidates molecular and immunovascular characteristics of macrotrabecular hepatocellular carcinoma. Hepatology. 2024; in press.

5. Yasukawa K, Shimada S, Akiyama Y, Taniai T, Igarashi Y, Tsukihara S, Tanji Y, Umemura K, Kamachi A, Nara A, Yamane M, Akahoshi K, Shimizu A, Soejima Y, Tanabe M, Tanaka S. ACVR2A attenuation impacts lactate production and hyperglycolytic conditions attracting regulatory T cells in hepatocellular carcinoma. Cell Reports Medicine. 2024; 6 (4): 102038-in press. ( PubMed, DOI )

6. Igarashi, Y; Akiyama, Y; Shimada, S; Watanabe, S; Hatano, M; Kodera, K; Okazaki, K; Tanji, Y; Tsukihara, S; Taniai, T; Nara, A; Yamane, M; Kamachi, A; Umemura, K; Yasukawa, K; Ono, H; Akahoshi, K; Tanabe, M; Haruki, K; Furukawa, K; Ikegami, T; Tanaka, S. Identification and clinical implications of endogenous retrovirus elements suppressed by SETDB1 in hepatocellular carcinoma JHEP REPORTS. 2025.03; 7 (3): 101307. ( PubMed, DOI )

7. Taniai, T; Shimada, S; Akiyama, Y; Hatano, M; Yasukawa, K; Igarashi, Y; Tsukihara, S; Tanji, Y; Kodera, K; Okazaki, K; Haruki, K; Nara, A; Yagi, K; Akahoshi, K; Ban, DSK; Asahina, Y; Ikegami, T; Tanabe, M; Tanaka, S. Integrative transcriptome profiling elucidates molecular and immunovascular characteristics of macrotrabecular HCC HEPATOLOGY. 2025.02; ( PubMed, DOI )

8. Shimada, S; Akiyama, Y; Akahoshi, K; Tanaka, S. Loss of SFXN1 mitigates lipotoxicity and predicts poor outcome in non-viral hepatocellular carcinoma CANCER SCIENCE. 2025.01; 116 1481.

9. Yamane M, Ishikawa Y, Yamashita H, Morimoto K, Asano D, Sugawara T, Watanabe S, Ueda H, Akahoshi K, Ono H, Tanaka S, Tanabe M. Middle segment preserving pancreatectomy versus total pancreatectomy: a comparative analysis of short- and long-term outcomes. Surgery Today. 2024.12; Online ahead of print.

10. Hatano M, Akiyama Y, Shimada S, Yagi K, Akahoshi K, Itoh M, Tanabe M, Ogawa Y, Tanaka S. Loss of KDM6B epigenetically confers resistance to lipotoxicity in nonalcoholic fatty liver disease-related hepatocellular carcinoma. Hepatology Communications. 2023.10; 7 (10): e0277.

11. Hatano, M; Akiyama, Y; Shimada, S; Yagi, K; Akahoshi, K; Itoh, M; Tanabe, M; Ogawa, Y; Tanaka, S. Loss of KDM6B epigenetically confers resistance to lipotoxicity in nonalcoholic fatty liver disease-related HCC HEPATOLOGY COMMUNICATIONS. 2023.10; 7 (10): ( PubMed, DOI )

12. Yamane M, Ishikawa Y, Asano D, Watanabe S, Ueda H, Akahoshi K, Ono H, Kudo A, Tanaka S, Sugiyama Y, Muro S, Akita K, Tanabe M. Surgical anatomy of the dorsal pancreatic artery: Considering embryonic development. Pancreatology. 2023.09; 23 (6): 697-703. ( PubMed, DOI )

13. Murota Y, Nagane M, Wu M, Santra M, Venkateswaran S, Tanaka S, Bradley N, Taga T, Tabu K. A niche-mimicking polymer hydrogel-based approach to identify molecular targets for tackling human pancreatic cancer stem cells. Inflammation and Regeneration. 2023.09; 43 (1): 46. ( PubMed, DOI )

14. Morimoto K, Ueda H, Asano D, Ishikawa Y, Watanabe S, Akahoshi K, Ono H, Kobayashi M, Okamoto R, Tanaka S, Tanabe M. Incidence and Mechanism of Refractory Postoperative Cholangitis After Hepatectomy with Hepaticojejunostomy. Journal of Gastrointestinal Surgery. 2023.06; 27 (8): 1668-1676.

15. Yagi K, Shimada S, Akiyama Y, Hatano M, Asano D, Ishikawa Y, Ueda H, Watanabe S, Akahoshi K, Ono H, Tanabe M, Tanaka S. Loss of SFXN1 mitigates lipotoxicity and predicts poor outcome in non-viral hepatocellular carcinoma. Sci Rep. 2023.06; 13 (1): 9449. ( PubMed, DOI )

16. Yamamoto Y, Shimada S, Akiyama Y, Tsukihara S, Sugimoto R, Kabashima A, Tokunaga M, Kinugasa Y, Kawakami Y, Tanaka S. RTP4 silencing provokes tumor-intrinsic resistance to immune checkpoint blockade in colorectal cancer. Journal of Gastroenterology. 2023.06; 58 (6): 540-553.

17. Yagi K, Ono H, Kudo A, Kinowaki Y, Asano D, Watanabe S, Ishikawa Y, Ueda H, Akahoshi K, Tanaka S, Tanabe M. MGMT is frequently inactivated in pancreatic NET-G2 and is associated with the therapeutic activity of STZ-based regimens. Sci Rep. 2023.05; 13 (1): 7535. ( PubMed, DOI )

18. Ono H, Murase Y, Yamashita H, Kato T, Asano D, Ishikawa Y, Watanabe S, Ueda H, Akahoshi K, Ogawa K, Kudo A, Akiyama Y, Tanaka S, Tanabe M. RRM1 is mediated by histone acetylation through gemcitabine resistance and contributes to invasiveness and ECM remodeling in pancreatic cancer. International Journal of Oncology. 2023.04; 62 (4): 51.

19. Ishii T, Akiyama Y, Shimada S, Kabashima A, Asano D, Watanabe S, Ishikawa Y, Ueda H, Akahoshi K, Ogawa K, Ono H, Kudo A, Tanabe M, Tanaka S. Identification of a novel target of SETD1A histone methyltransferase and the clinical significance in pancreatic cancer. Cancer Science. 2023.02; 114 (2): 463-476.

20. Shimada, S; Akiyama, Y; Tanaka, S. Intrinsic activation of β-catenin signaling by CRISPR/Cas9-mediated exon skipping contributes to immune evasion in HCC CANCER SCIENCE. 2023.02; 114 125.